Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Unusually-High Trading Volume – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw unusually-strong trading volume on Friday . Approximately 3,000 shares traded hands during mid-day trading, an increase of 283% from the previous session’s volume of 783 shares.The stock last traded at $72.2034 and had previously closed at $73.75.

Analyst Upgrades and Downgrades

ZLDPF has been the subject of a number of research reports. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday, December 16th. Finally, Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a report on Monday, September 15th. Six analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Strong Buy”.

Zealand Pharma A/S Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10. The stock’s 50-day moving average is $76.73 and its two-hundred day moving average is $68.42. The stock has a market cap of $5.13 billion, a PE ratio of 5.19 and a beta of 0.75.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.21. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%.The company had revenue of $7.76 million for the quarter, compared to analysts’ expectations of $4.54 million. On average, equities analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.